Solid Biosciences LLC

Company Profile

Solid Biosciences LLC had its IPO on 2018-01-26 under the ticker symbol SLDB.

The company operates in the Healthcare sector and Biotechnology industry. Solid Biosciences LLC has a staff strength of 87 employees.

Stock update

Shares of Solid Biosciences LLC opened at $3.33 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $3.28 - $3.47, and closed at $3.35.

This is a +1.21% increase from the previous day's closing price.

A total volume of 18,866 shares were traded at the close of the day’s session.

In the last one week, shares of Solid Biosciences LLC have slipped by -7.46%.

Solid Biosciences LLC's Key Ratios

Solid Biosciences LLC has a market cap of $72.62 million, indicating a price to book ratio of 0.9036 and a price to sales ratio of 11.8924.

In the last 12-months Solid Biosciences LLC’s revenue was $0 with a gross profit of $13.62 million and an EBITDA of $-106593000. The EBITDA ratio measures Solid Biosciences LLC's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Solid Biosciences LLC’s operating margin was 0% while its return on assets stood at -32.97% with a return of equity of -55.38%.

In Q2, Solid Biosciences LLC’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Solid Biosciences LLC’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-6.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Solid Biosciences LLC’s profitability.

Solid Biosciences LLC stock is trading at a EV to sales ratio of 1.1559 and a EV to EBITDA ratio of -0.1505. Its price to sales ratio in the trailing 12-months stood at 11.8924.

Solid Biosciences LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$204.72 million

Total Liabilities

$15.87 million

Operating Cash Flow

$0

Capital Expenditure

$536000

Dividend Payout Ratio

0%

Solid Biosciences LLC ended 2024 with $204.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $204.72 million while shareholder equity stood at $163.73 million.

Solid Biosciences LLC ended 2024 with $0 in deferred long-term liabilities, $15.87 million in other current liabilities, 20000.00 in common stock, $-617437000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $91.57 million and cash and short-term investments were $160.19 million. The company’s total short-term debt was $2,272,000 while long-term debt stood at $0.

Solid Biosciences LLC’s total current assets stands at $167.48 million while long-term investments were $0 and short-term investments were $68.62 million. Its net receivables were $0 compared to accounts payable of $2.97 million and inventory worth $0.

In 2024, Solid Biosciences LLC's operating cash flow was $0 while its capital expenditure stood at $536000.

Comparatively, Solid Biosciences LLC paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$3.35

52-Week High

$9.72

52-Week Low

$3.21

Analyst Target Price

$7.33

Solid Biosciences LLC stock is currently trading at $3.35 per share. It touched a 52-week high of $9.72 and a 52-week low of $9.72. Analysts tracking the stock have a 12-month average target price of $7.33.

Its 50-day moving average was $4.15 and 200-day moving average was $5.46 The short ratio stood at 3.36 indicating a short percent outstanding of 0%.

Around 105% of the company’s stock are held by insiders while 8054.7% are held by institutions.